You have clicked on a link which leaves Fresenius Kabi’s website and you will be redirected to a third-party website. Fresenius Kabi makes no representations nor has any supervision or control over the quality, content, reliability, or security of the third-party website, nor shall Fresenius Kabi be liable for its use.
As pioneers in clinical nutrition, our innovations nourish at every age and stage of life. Our parenteral nutrition (PN) products are used to help care for critically ill and chronically ill patients in hospitals, long-term care facilities, and at home. We’re proud to be the U.S. market leader in lipid injectable emulsions (ILEs).1
Optimal nutritional support is critical for COVID-19 patients in the ICU, which is why experts recommend considering alternative ILEs for this patient population.2 As an early pioneer in alternative mixed lipid emulsions, Fresenius Kabi is expanding clinical nutrition options for critically ill patients.
A tireless dedication to driving advancements in lifesaving medicines and technologies has led to many firsts in the field, like introducing the first lipid PN product for adults in more than 40 years, keeping Fresenius Kabi at the forefront of PN.
Developed the first and only three-chamber bag for adult PN in the U.S.
Pioneered the use of fish oil and omega-3s in PN products
Brought the benefits of alternative lipid emulsions to market
Developed the only pediatric lipid ILE product for PN-associated cholestasis (PNAC) in the U.S.
The first four-oil ILE product approved for pediatric patients including term and preterm neonates
References: 1. Data on File; 6/1/22; calculation includes: all ILEs approved in the US. 2. Martindale R, Patel JJ, Taylor B, et al. Nutrition therapy in critically ill patients with coronavirus disease 2019. JPEN J Parenter Enteral Nutr. 2020;44(7):1174-1184. 3. Vanek VW, Seidner DL, Allen P, et al. Novel Nutrient Task Force, Intravenous Fat Emulsions Workgroup; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192. doi:10.1177/0884533612439896